Clinical Trial Update: A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lebekizumab for airway eosinophilic inflammation in uncontrolled asthma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Asthma | Phase 2 | Status: COMPLETED